AzTrials
AzTrials

Rheumatoid ArthritisPhase 3NCT00771251

A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)

A Phase 3 study testing CNTO 148 in people with Rheumatoid Arthritis, run by Janssen Pharmaceutical K.K. at 67 sites in Japan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the safety and effectiveness of golimumab in patients with active rheumatoid arthritis despite DMARD (Disease-modifying antirheumatic drugs) therapy. Another objective is to evaluate the pharmacokinetics of golimumab. Read more about this study

Who is it for?
Ages 20 to 74 years
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
CNTO 148
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
311 participants
Where
67 sitesJapan
Study dates
May 2008to Oct 2011
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 74 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients diagnosed with rheumatoid arthritis at least 3 months prior to registration and who are definitely identified as having rheumatoid arthritis, at the time of informed consent, according to the criteria for classification established by the American College of Rheumatology (1987)
  • Patients who have previously not responded to at least one DMARD (before informed consent is obtained)
  • Patients who, if they are on the treatment with a DMARD, the DMARD can be washed out for at least 4 weeks before the first administration
  • Patients having at least 6 swollen joints and 6 tender joints at the time of registration and immediately before the first injection

Who cannot join

  • Patients with a history of hypersensitivity to human immunoglobulin proteins or other ingredients of golimumab
  • Patients who have previously experienced or are suffering from any of the following diseases: (i) Collagen diseases other than rheumatoid arthritis, (ii) Latent or active granulomatous infections such as histoplasmosis and coccidioidomycosis, (iii) Felty syndrome, etc
  • Patients with a severe, advanced, or poorly controlled disease in any of the kidney, liver, blood, gastrointestinal system, endocrine system, lung, heart, nervous system, psychiatric system, and brain

Trial locations and contacts

67 sites in 1 country.

67 sites in 1 country

Japan67 sites

  • Study site

    Asahikawa

  • Study site

    Ayauta

  • Study site

    Azumino

  • Study site

    Chiba

  • Study site

    Fuchū

  • Study site

    Fukui

  • Study site

    Fukuoka

  • Study site

    Fukushima

  • Study site

    Gifu

  • Study site

    Goshogawara

  • Study site

    Hachiōji

  • Study site

    Hamamatsu

  • Study site

    Higashi-Hiroshima

  • Study site

    Hiki

  • Study site

    Hiroshima

  • Study site

    Hitachi

  • Study site

    Hitachi-Naka

  • Study site

    Iruma

  • Study site

    Izumisano

  • Study site

    Izumo

  • Study site

    Kamakura

  • Study site

    Katō

  • Study site

    Kawachi-Nagano

  • Study site

    Kawagoe

  • Study site

    Kawasaki

  • Study site

    Kita-Gun

  • Study site

    Kitakyushu

  • Study site

    Kitamoto

  • Study site

    Kobe

  • Study site

    Kumamoto

  • Study site

    Kyoto

  • Study site

    Matsue

  • Study site

    Matsumoto

  • Study site

    Matsuyama

  • Study site

    Nagano

  • Study site

    Nagoya

  • Study site

    Narashino

  • Study site

    Niigata

  • Study site

    Nishinomiya

  • Study site

    Ohta-Ku

  • Study site

    Ōita

  • Study site

    Osaka

  • Study site

    Ōsaka-sayama

  • Study site

    Ōsaki

  • Study site

    Sagamihara

  • Study site

    Saitama

  • Study site

    Sapporo

  • Study site

    Sasebo

  • Study site

    Sendai

  • Study site

    Shimotsuga

  • Study site

    Shimotsuke

  • Study site

    Shinjuku-Ku

  • Study site

    Shizuoka

  • Study site

    Suita

  • Study site

    Tokushima

  • Study site

    Tokyo

  • Study site

    Tomigusuku

  • Study site

    Toshima-Ku

  • Study site

    Toyama

  • Study site

    Toyoake

  • Study site

    Toyohashi

  • Study site

    Tsu

  • Study site

    Tsukuba

  • Study site

    Tsukubo

  • Study site

    Ube

  • Study site

    Yokohama

  • Study site

    Yufu

Other trials in Japan

About this study

Official title: A Study of Golimumab (CNTO148) Monotherapy in Patients With Active Rheumatoid Arthritis

The purpose of this study is to evaluate the safety and effectiveness of golimumab in patients with active rheumatoid arthritis despite DMARD (Disease-modifying antirheumatic drugs) therapy. Another objective is to evaluate the pharmacokinetics of golimumab.

Read the detailed description

This study is designed as a placebo-controlled study of golimumab monotherapy for the purpose of demonstrating the safety and effectiveness of golimumab, a new, fully human anti-TNF (Tumor necrosis factor) a monoclonal antibody produced by mean of HuMab mouse technology. Other reasons for using the study design are as follows: the effects of golimumab given alone must be confirmed as in the case of other drugs; and golimumab may be used even in patients not on the treatment with methotrexate (MTX). There will be 3 treatment groups in the study as follows: CNTO148 50 mg group, CNTO 148 100 mg group, and Placebo group.

Being tested
CNTO 148, Placebo
Keywords
Rheumatoid arthritis, Fully Human anti-TNFa monoclonal antibody, CNTO148, Golimumab
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CNTO 148Drug

    Also called Golimumab

    50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 116.

  • PlaceboDrug

    Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks until week 12 and then CNTO148 50mg SC injections every 4 weeks from week 16 until week 116.

Study groups in NCT00771251
Study groupRoleWhat they receive
CNTO 148 50 mgExperimentalNot described
Receives: Drug: CNTO 148
CNTO 148 100 mgExperimentalNot described
Receives: Drug: CNTO 148
PlaceboExperimentalNot described
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. ACR 20% response

    Measured: Weel 14

Secondary outcomes (1)

  1. ACR 50% response, ACR 70% response, ACR 90% response, Changes from the pretreatment values in the DAS (Disease Activity Score) 28, and the HAQ (Health assessment questionnaire)

    Measured: Week 14

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Oct 2008 (estimated)
  2. Study startMay 2008
  3. Primary completionOct 2011
  4. Study completionOct 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
311 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00771251
Sponsor's protocol ID
CR015343
Other IDs
JNS012-JPN-04
Status last verified
Nov 2015
First submitted
10 Oct 2008
Last updated
3 Nov 2015
Results posted
No
Data monitoring committee
No

Publications

  • Takeuchi T, Harigai M, Tanaka Y, Yamanaka H, Ishiguro N, Yamamoto K, Miyasaka N, Koike T, Kanazawa M, Oba T, Yoshinari T, Baker D; GO-MONO study group. Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks. Ann Rheum Dis. 2013 Sep 1;72(9):1488-95. doi: 10.1136/annrheumdis-2012-201796. Epub 2012 Sep 14.

    PubMed 22984173

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing CNTO 148 in people with Rheumatoid Arthritis, run by Janssen Pharmaceutical K.K. at 67 sites in Japan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Nov 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 67 sites in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

ACR 20% response (time frame: Weel 14). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00771251, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2015.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in